Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Demopoulos

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology|August 10, 2000
Modulation of vascular endothelial gene expression by physical training in patients with chronic heart failureM Testa, P V Ennezat, K L Vikstrom, et al.
The New England Journal of Medicine|June 23, 2001
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularizationE J Topol, D J Moliterno, H C Herrmann, et al.
The American Journal of Cardiology|March 11, 1999
Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban]] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trialW S Weintraub, S D Culler, A Kosinski, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology|August 10, 2000
Modulation of vascular endothelial gene expression by physical training in patients with chronic heart failureM Testa, P V Ennezat, K L Vikstrom, et al.
The New England Journal of Medicine|June 23, 2001
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularizationE J Topol, D J Moliterno, H C Herrmann, et al.
The American Journal of Cardiology|March 11, 1999
Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban]] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trialW S Weintraub, S D Culler, A Kosinski, et al.
Pageof 2